Sara Tolaney, MD, MPH
With the FDA approval of neratinib (Nerlynx) earlier this year, and the recent priority review designation of pertuzumab (Perjeta), treatment options for patients with HER2-positive breast cancer continue to advance.
, Tolaney, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discussed the state of adjuvant treatment for patients with HER2-positive breast cancer.
OncLive: What does the adjuvant landscape look like in HER2-positive disease?
: [Adjuvant treatment for HER2-positive breast cancer] has evolved over the past few years. We have seen outcomes from 6 pivotal studies that have shown that adding trastuzumab to chemotherapy dramatically improves disease-free and overall survival. Despite this, 15% of patients with HER2-positive cancer still recur. There has been a need to try to do more to improve outcomes. There are 2 particular drugs that I focused on; one was pertuzumab and the other was neratinib.
... to read the full story